GLENN ALLEN, Va.--(BUSINESS WIRE)--July 5, 2006--On Friday, June 30, 2006, the U.S. District Court for the Northern District of California issued a decision in the suit brought by Tercica Inc and Genentech, Inc against Insmed, Inc.(NASDAQ:INSM - News) and two of its subsidiaries alleging infringement of three U.S. patents. The Court ruled on issues of claim construction and on motions by both sides for partial summary judgment. The Court adopted some claim interpretations proposed by Plaintiffs and others proposed by Insmed. It also adopted some interpretations that were modifications of those proposed by the parties. The Court likewise granted certain motions for summary judgment and denied others. The Court's rulings do not fully resolve all of the pending issues regarding any of the three patents. The remaining issues will be resolved at trial, which is currently scheduled to commence on November 6, 2006. The decision does not have any impact on Insmed's ability to continue to sell IPLEX. (TM).
